#Denmark #Copenhagen #Cancer Immunotherapy #HERVolution #HERV-K

HERVolution's Groundbreaking Research on HERV-K Antigens

HERVolution Therapeutics ApS has taken a monumental step in the fight against cancer with the publication of pivotal research on its HERV-K platform in the esteemed Journal of Translational Medicine. The study elucidates the engineering of human endogenous retrovirus (HERV)-K antigens, demonstrating their ability to disrupt immune tolerance and adequately train immune cells to target cancer cells effectively, potentially reshaping oncology treatments.

Introduction to HERV-K

The focus of this innovative research is the HERV-K antigen, selected for its extensive expression across a wide array of human cancers. The peer-reviewed article titled "Engineering human endogenous retrovirus-K for improving immunogenicity and broad cancer targeting" is accessible online, highlighting the significance of HERV-K as a broad tumor antigen.

Research Findings

The HERVolution study analyzed RNA sequencing data from 1,353 cancer patients. Its results showed that HERV-K expression is prevalent across numerous cancer types, indicating that an approach targeting HERV-K could yield promising therapeutic benefits for many patients. This expansive expression suggests that HERV-K-directed therapies might have broad application potential.

Moreover, through meticulous protein engineering, the researchers have successfully altered the immunosuppressive nature of HERV-K's envelope protein. The modification involved identifying a specific mutation within the protein that enhances immune recognition, thus breaking the body's inherent tolerance towards these viral antigens.

Mechanism of Action

The enhanced recognition of HERV-K by the immune system was evidenced by the activation of T cells capable of targeting cancer cells. Upon transduction with adenoviral vectors containing the engineered antigen, dendritic cells from healthy donors prompted the proliferation of both CD4+ and CD8+ T cells. These T cells showed a robust response against lung cancer cell lines, marking a critical knowledge advancement in harnessing the immune system for therapeutic purposes.

In preclinical studies on mice and macaques, the engineered HERV-K antigens elicited robust immune responses, showcasing potential effectiveness in treating metastatic cancers. Such groundbreaking outcomes support the notion of combining HERV-K therapies with existing immunotherapies, such as anti-PD-1 treatments, to enhance tumor clearance and improve patient survival rates.

Future Implications

HERVolution's publication coincides with its clinical progression as HERV-K is poised to enter clinical trials as a viable vaccine target. The recent approval from the U.S. Food and Drug Administration (FDA) for a self-amplifying RNA vaccine that includes HERV-K suggests strong regulatory acceptance of this innovative approach.

This affirmation of HERV-K's therapeutic potential bolsters the pathway for HERVolution’s lead therapy, IPT-001, aiming to enter first-in-human studies targeting both oncology and metabolic diseases. HERVolution’s strategic focus on the HERV-K platform demonstrates a commitment to pioneering progressive therapies that could redefine treatment methodologies in cancer care.

Expert Insights

Dr. J. Robert Coleman, CEO of HERVolution Therapeutics, emphasized the significance of the publication, stating, "It establishes that HERV-K is expressed across the vast majority of cancers, that it can be rationally re-engineered to break immune tolerance, and that the resulting immune response effectively reaches human tumor cells."

Dr. Peter Johannes Holst, Chief Scientific Officer at HERVolution, noted that these modifications signal a breakthrough in the field of immunotherapy, enhancing both T cell and B cell responses against tumors.

Conclusion

The foundational data released by HERVolution Therapeutics marks a promising development in cancer immunotherapy. With HERV-K emerging as a target class, the company is well-positioned to advance its innovative solutions aimed at combating cancer, metabolic diseases, and more,—with the ultimate goal of delivering effective treatments that harness the body’s own immune capabilities to fight disease.

Through continued research and collaboration, the potential of HERV-K stands to significantly impact future approaches in cancer treatment, offering hope to patients and advancing the field of oncology.